May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More
December 12, 2022
Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition
American Society of Hematology Annual Meeting and Expo
Other
Read More
December 12, 2022
Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader
American Society of Hematology Annual Meeting and Expo
Other
Read More
December 11, 2022
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia
American Society of Hematology Annual Meeting
Other
Read More
December 7, 2022
Proteomics enabling TPD Drug Discovery
TPD Assay Development and Screening Summit
Read More
October 27, 2022
Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors
5th Annual Targeted Protein Degradation (TPD) Summit
Other
Read More
October 26, 2022
The Phase 1 Healthy Volunteer Clinical Trial of KT-474
5th Annual Targeted Protein Degradation (TPD) Summit
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More
October 26, 2022
Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study
5th Annual Targeted Protein Degradation (TPD) Summit
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More
October 25, 2022
Expression & Characterization of Novel Tissue Selective E3 Ligases
5th Annual Targeted Protein Degradation (TPD) Summit
Read More
October 19, 2022
KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo
20th Annual Discovery on Target Conference
Other
Read More